Dr. Maria I. Quejada
Claim this profileElmhurst Memorial Hospital
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
7 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Maria I. Quejada is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Radiation Therapy + Atezolizumab
for Small Cell Lung Cancer
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
Recruiting1 award Phase 2 & 311 criteria
More about Maria I. Quejada
Clinical Trial Related11 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Maria I. Quejada has experience with
- Biospecimen Collection
- Crizotinib
- Carboplatin
- Pembrolizumab
- Pemetrexed
- Atezolizumab
Breakdown of trials Maria I. Quejada has run
Lung Cancer
Non-Small Cell Lung Cancer
Anaplastic Large Cell Lymphoma
ALK Gene Rearrangement
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Maria I. Quejada specialize in?
Maria I. Quejada focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Maria I. Quejada currently recruiting for clinical trials?
Yes, Maria I. Quejada is currently recruiting for 2 clinical trials in Elmhurst Illinois. If you're interested in participating, you should apply.
Are there any treatments that Maria I. Quejada has studied deeply?
Yes, Maria I. Quejada has studied treatments such as Biospecimen Collection, Crizotinib, Carboplatin.
What is the best way to schedule an appointment with Maria I. Quejada?
Apply for one of the trials that Maria I. Quejada is conducting.
What is the office address of Maria I. Quejada?
The office of Maria I. Quejada is located at: Elmhurst Memorial Hospital, Elmhurst, Illinois 60126 United States. This is the address for their practice at the Elmhurst Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.